tbuckley/cabot-search huggingface dataset:
Effect of Donor Recipient Age Match on Survival after First Deceased Donor Renal Transplantation
Authors: Douglas S. Keith, Angelo Demattos, Muralikrishna Golconda, Jonathan Prather, Douglas Norman
Journal: Journal of the American Society of Nephrology (2004)

Donor-recipient age matching has been proposed as a means of improving overall outcomes in deceased donor renal transplantation. It was hypothesized that donor-recipient age matching would improve patient survival time in younger recipients while not adversely affecting patient survivals in older recipients because they seldom outlive their grafts. By use of data from United Network of Organ Sharing Standard Transplant and Analysis and Research Files 50,320 patients were identified who underwent a first deceased donor renal transplantation between January 1, 1990, and December 31, 1997. Adjusted patient survival and death-with-graft function patient survival were analyzed from the date of transplantation. Patient survival was affected by donor age for all recipient age groups, including recipients older than 55 yr. The effect of donor age on patient survival is greater than that seen with HLA matching. The effect of donor age on patient survival persisted even when censoring recipients in whom grafts failed before death, suggesting that both longevity and quality of graft function are important in patient survival. Donor-recipient age matching is occurring to a limited degree in this population. Donor-recipient age matching would improve survival in younger recipients but would adversely affect survival in older patients by reducing the availability of younger donor kidneys for this group. The issue of donor-recipient age matching needs to be debated among the public and transplantation community so that a logical and just system can be developed.
Optimization in organic synthesis
Authors: Victor Snieckus
Journal: Medicinal Research Reviews (1999)

Art is always a bonus to synthesis . . . . the artistic aspect of synthesis, beautiful and marvelous as it is, should not be a justification for carrying out a total synthesis.If your problem is truly essential then you don't care about the elegance.The more essential your first E is, the less important your last E becomes." 1 "Will we be able to recapture the many millions of presumed 'transient'natural products that were evolutionarily de-selected along the paths that eventually led to the natural products synthesized on Earth today? . . .I cannot imagine that in a young synthetic chemist's lifetime, it will not be accomplished." 2
Irinotecan Plus Temozolomide for Relapsed or Refractory Neuroblastoma
Authors: Brian H. Kushner, Kim Kramer, Shakeel Modak, Nai-Kong V. Cheung
Journal: Journal of Clinical Oncology (2006)

To report on an irinotecan and temozolomide regimen for neuroblastoma (NB). Quality of life and minimizing toxicity were major considerations.The plan stipulated 5-day courses of irinotecan 50 mg/m2 (1-hour infusion) and temozolomide 150 mg/m2 (oral) every 3 to 4 weeks, with a pretreatment platelet count more than 30,000/microL. Granulocyte colony-stimulating factor was used when the absolute neutrophil count was less than 1,000/microL.Forty-nine NB patients received 1 to 15 courses (median, 5). Gastrointestinal and myelosuppressive toxicities were readily managed. Lymphocyte responses to phytohemagglutinin after 2 to 10 courses (median, 3.5) were normal in 10 of 10 patients treated after nonimmunosuppressive therapy, and normalized in five of seven patients first treated less than 2 months after high-dose alkylators. Of 19 patients treated for refractory NB and assessable for response, nine showed evidence of disease regression, including two complete responses and seven objective responses. Of 17 patients treated for progressive disease, three showed evidence of disease regression, including one partial response and two objective responses. Multiple courses entailed no cumulative toxicity and controlled disease for prolonged periods in many patients, including some who were unable to complete prior treatments because of hematologic, infectious, cardiac, or renal problems.This regimen has anti-NB activity, spares vital organs, is feasible with poor bone marrow reserve, causes limited immunosuppression, and allows good quality of life.
Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry
Authors: Jan Beyer-Westendorf, Kati Förster, Sven Pannach, Franziska Ebertz, Vera Gelbricht, Christoph Thieme, Franziska Michalski, Christina Köhler, Sebastian Werth, Kurtulus Sahin, Luise Tittl, Ulrike Hänsel, Norbert Weiss
Journal: Blood (2014)
Thyroid-Stimulating Hormone, Thyroglobulin, and Thyroid Hormones and Risk of Differentiated Thyroid Carcinoma: The EPIC Study
Authors: Sabina Rinaldi, Martyn Plummer, Carine Biessy, Konstantinos K. Tsilidis, Jane Nautrup Østergaard, Kim Overvad, Anne Tjønneland, Jytte Halkjær, Marie-Christine Boutron-Ruault, Françoise Clavel-Chapelon, Laure Dossus, Rudolf Kaaks, Annekatrin Lukanova, Heiner Boeing, Antonia Trichopoulou, Pagona Lagiou, Dimitrios Trichopoulos, Domenico Palli, Claudia Agnoli, Rosario Tumino, Paolo Vineis, Salvatore Panico, H. Bas Bueno-de-Mesquita, Petra H Peeters, Elisabete Weiderpass, Eiliv Lund, J. Ramón Quirós, Antonio Agudo, Esther Molina, Nerea Larrañaga, Carmen Navarro, Eva Ardanaz, Jonas Manjer, Martin Almquist, Maria Sandström, Joakim Hennings, Kay-Tee Khaw, Julie Schmidt, Ruth C. Travis, Graham Byrnes, Augustin Scalbert, Isabelle Romieu, Marc Gunter, Elio Riboli, Silvia Franceschi
Journal: JNCI Journal of the National Cancer Institute (2014)

Increased levels of thyroglobulin (Tg) and thyroid-stimulating hormone (TSH) are associated with differentiated thyroid carcinoma (TC) risk, but strong epidemiological evidence is lacking.
The incidence and risk of second primary cancers in patients with nasopharyngeal carcinoma: a population-based study in Taiwan over a 25-year period (1979–2003)
Authors: M.-C. Chen, I.-J. Feng, C.-H. Lu, C.-C. Chen, J.-T. Lin, S.-H. Huang, K.-D. Lee
Journal: Annals of Oncology (2008)
Identifying malnourished children may not be easy
Authors: F. van Leth
Journal: BMJ (2003)

EDITOR—Bahn et al propose to use the World Health Organization's criteria for diagnosing malnutrition,1 which include calculating Z scores for weight for height, and height for age.

Rural hospitals in resource poor areas are often severely understaffed but at the same time have high admission rates of especially small children. The amount of strain that measuring the heights …
Glomerular Ultrafiltration in Normal and Preeclamptic Pregnancy
Authors: Paul Moran, Peter H. Baylis, Marshall D. Lindheimer, John M. Davison
Journal: Journal of the American Society of Nephrology (2003)

ABSTRACT. GFR and renal plasma flow (RPF) decrease in preeclampsia, a serious hypertensive complication of pregnancy. Serial data derived in late pregnancy (LP) and >5 mo postpartum (PP) in 13 healthy controls and 10 preeclamptic women (13 and 5, respectively) returning PP for theoretical analysis of neutral dextran sieving curves (θD), are presented and are used to calculate the key determinants of glomerular ultrafiltration. Normal LP hyperfiltration was associated with increases in RPF and the ultrafiltration coefficient (Kf), as well as in the nondiscriminatory shunt pathway (ω0) and the SD of pore size (S). Preeclamptic LP showed the largest ω0 and S values, indicating a loss of size-selectivity, accompanying reduced Kf and RPF, both of which are implicated in the relative hypofiltration. Despite a 100-fold increase in urinary albumin excretion (UAE), LP preeclamptic θD values were reduced for the equivalent neutral dextran (36A[Combining Ring Above]), providing indirect evidence for a loss of glomerular barrier charge-selectivity. All the determinants of GFR and all modeled parameters were comparable across both groups PP, strong evidence that preeclamptic glomerular dysfunction resolves. E-mail: [email protected]
Body contour for radiotherapy.
Authors: D E Brown
Journal: BMJ (1970)

against re-exposure to the same virus in later years.Approximately every decade a major antigenic variant of influenza A virus appears which can infect those immunized by experience of the previous subtype; these individuals have also been sensitized by their previous exposure to the many antigens shared by the new variant with its pre- decessors of the same type.Thus an allergic element in the response to infection of the older cohort may be respon- sible for the typically febrile "influenzal" illness and for the fulminating haemorrhagic pneumonias and encephalitis found particu- larly in later childhood and early adult years.Most older adults may have acqiiired sufficient protective immunity from a series of infections with sequential new influenza A subtypes to inhibit the more damaging cross-sensitization effects of infection with the latest subtype.-Iam, etc.,
Evidence for a dual innervation affecting local blood flow in the hypothalamus of the conscious rabbit.
Authors: C Rosendorff, G Mitchell, D R Scriven, C Shapiro
Journal: Circulation Research (1976)

We have attempted to evaluate the role of adrenergic nerves which arise from the superior cervical ganglia or which are intracerebral throughout their course, in the control of local cerebral blood flow (CBF). Hypothalamic blood flow (HBF) was measured in the conscious rabbit by the 133Xe-clearance technique. Stimulation of the upper brainstem, using 5-Hz, 3-V, 1-msec, square wave pulses, increased by HBF by a mean of 7.6 ml/100 g per min (P less than 0.005). This effect was abolished by the intrahypothalamic injection of the beta-adrenoreceptor blocker, propranolol, and by chemical sympathectomy of the hypothalamus or of the upper brainstem with 6-hydroxydopamine, but was not altered by bilateral cervical ganglionectomy. Intrahypothalamic injection of 0.1 mug of tyramine caused a mean decrease in HBF of 15.6 ml/100 g per min (P less than 0.001). This effect of intrahypothalamic injection of tyramine was abolished by bilateral cervical sympathectomy but not by chemical sympathectomy of the upper brainstem. These results support the idea that local CBF, at least in the hypothalamus, is mediated by two distinct pathways. The first consists of the sympathetic nerves which arise in the cervical ganglia, and which activate intrahypothalamic alpha-receptors to cause constriction. The second is an entirely intracerebral noradrenergic pathway which stimulates beta-receptors to cause vasodilation.
Feasibility of precompetition medical assessment at FIFA World Cups for female youth players
Authors: Jiri Dvorak, Katharina Grimm, Christian Schmied, Astrid Junge
Journal: British Journal of Sports Medicine (2011)

Background Although most experts agree that preparticipation screening is important to prevent sudden cardiac death in sport, only a few reports have been published on the feasibility of its practical implementation. Methods The football associations participating in the U-17 and U-20 Women's World Cups 2010 were asked to perform a standardised precompetition medical assessment (PCMA) of their players (in total 672). Results Compliance with the requirement for performing the PCMA was high among all teams, particularly from African, Asian and Central/South American countries. No relevant abnormal findings in personal history and clinical cardiological examination were reported. Athletic ECG patterns were frequent, but very few findings were considered to require further investigation. All players were declared as eligible to play. Conclusions Based on the demonstrated feasibility of performing a comprehensive PCMA in elite female youth players, the Fédération Internationale de Football Association (FIFA) Executive Committee decided to make the PCMA a compulsory requirement for all FIFA competitions.
Reliability assessment and validation of the postacne hyperpigmentation index (PAHPI), a new instrument to measure postinflammatory hyperpigmentation from acne vulgaris
Authors: Stephanie A. Savory, Nnenna G. Agim, Rui Mao, Shayna Peter, Casey Wang, Gerardo Maldonado, Jessica Bearden Dietert, Tiffany Jane Lieu, Christy Wang, Kara Pretzlaff, Shinjita Das, Travis Vandergriff, Isha E. Lopez, Brandon R. Litzner, Linda S. Hynan, Maria Ivonne Arellano-Mendoza, Paul R. Bergstresser, Amit G. Pandya
Journal: Journal of the American Academy of Dermatology (2013)
Use of alteplase in childhood arterial ischaemic stroke: a multicentre, observational, cohort study
Authors: Catherine Amlie-Lefond, Gabrielle deVeber, Anthony K Chan, Susan Benedict, Timothy Bernard, Jessica Carpenter, Michael M Dowling, Heather Fullerton, Collin Hovinga, Adam Kirton, Warren Lo, Khaled Zamel, Rebecca Ichord
Journal: The Lancet Neurology (2009)
A Role for Msh6 But Not Msh3 in Somatic Hypermutation and Class Switch Recombination
Authors: Stella A. Martomo, William W. Yang, Patricia J. Gearhart
Journal: The Journal of Experimental Medicine (2004)

Somatic hypermutation is initiated by activation-induced cytidine deaminase (AID), and occurs in several kilobases of DNA around rearranged immunoglobulin variable (V) genes and switch (S) sites before constant genes. AID deaminates cytosine to uracil, which can produce mutations of C:G nucleotide pairs, and the mismatch repair protein Msh2 participates in generating substitutions of downstream A:T pairs. Msh2 is always found as a heterodimer with either Msh3 or Msh6, so it is important to know which one is involved. Therefore, we sequenced V and S regions from Msh3- and Msh6-deficient mice and compared mutations to those from wild-type mice. Msh6-deficient mice had fewer substitutions of A and T bases in both regions and reduced heavy chain class switching, whereas Msh3-deficient mice had normal antibody responses. This establishes a role for the Msh2-Msh6 heterodimer in hypermutation and switch recombination. When the positions of mutation were mapped, several focused peaks were found in Msh6(-/-) clones, whereas mutations were dispersed in Msh3(-/-) and wild-type clones. The peaks occurred at either G or C in WGCW motifs (W = A or T), indicating that C was mutated on both DNA strands. This suggests that AID has limited entry points into V and S regions in vivo, and subsequent mutation requires Msh2-Msh6 and DNA polymerase.
A Day in the Life of a Corporate Retail Pharmacist
Authors: David D. Dore
Journal: Annals of Internal Medicine (2013)

On Being a DoctorSeptember 3, 2013A Day in the Life of a Corporate Retail PharmacistDavid D. Dore, PharmD, PhDDavid D. Dore, PharmD, PhDFrom The Warren Alpert Medical School of Brown University, Providence, Rhode Island.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-159-5-201309030-00014 Audio Reading - “A Day in the Life of a Corporate Retail Pharmacist” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "A Day in the Life of a Corporate Retail Pharmacist," by D.D. Dore. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail It was the Tuesday after Memorial Day and my fourth consecutive 13-hour day in the pharmacy. Having just passed the boards, I landed a job as a floating staff pharmacist. It was my first time working at this store and my third store in as many days. I did not know what to expect except that, as usual, I would be the only licensed pharmacist working here today. This fact struck me as a microcosm of my profession's ineffectualness—an ineffectualness resulting from misaligned objectives and poor processes of care, afflicting first pharmacists and, ultimately, patient care.Today's store was small ... Author, Article, and Disclosure InformationAffiliations: From The Warren Alpert Medical School of Brown University, Providence, Rhode Island.Corresponding Author: David D. Dore, PharmD, PhD, Brown University, Box G-121-7, 121 South Main Street, Providence, RI 02903; e-mail, [email protected]. PreviousarticleNextarticle Advertisement Audio Reading - “A Day in the Life of a Corporate Retail Pharmacist” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "A Day in the Life of a Corporate Retail Pharmacist," by D.D. Dore. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics Cited byA Day in the Life of a Corporate Retail PharmacistTina Penick Brock, EdD September 3, 2013Volume 159, Issue 5Page: 366-367KeywordsAnxietyComputersDrug administrationDrug policyDrug therapyDrugsFatigueFoodForecastingHealth care providersHeartInpatientsMyocardial infarctionNursesOverweightPatientsPharmacistsPhysiciansRisk managementTechnicians ePublished: 3 September 2013 Issue Published: September 3, 2013 Copyright & PermissionsCopyright © 2013 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
A Study of Circulatory Dynamics by Means of Crystal Radiation Detectors on the Anterior Thoracic Wall
Authors: REX L. HUFF, DANIEL PARRISH, WAYNE CROCKETT
Journal: Circulation Research (1957)

A description is given of simultaneous tape records from four well-shielded crystal detectors placed on the anterior chest in the projections of the right atrium, pulmonary artery, ventricles, and lung vessels alone. Single intravenous injections of J 131 human serum albumin were made. Cardiac outputs calculated from the observed data compare favorably with those obtained by catherization. Use of the tape recorder with slow playback speeds allows for unique storage, transformation and interpretation of data. Characteristic curves obtained from patients with congenital and valvular heart disease are analyzed.
RACE INFLUENCES THE SAFETY AND EFFICACY OF SPIRONOLACTONE IN SEVERE HEART FAILURE
Authors: Orly Vardeny, Larisa H. Cavallari, Brian Claggett, Inderjit Anand, Akshay Desai, Patrick Rossignol, Faiez Zannad, Bertram Pitt, Scott Solomon
Journal: Journal of the American College of Cardiology (2013)
Common burden of chronic skin diseases? Contributors to psychological distress in adults with psoriasis and atopic dermatitis
Authors: A.W.M. Evers, Y. Lu, P. Duller, P.G.M. van der Valk, F.W. Kraaimaat, P.C.M. van de Kerkhof
Journal: British Journal of Dermatology (2005)

Chronic skin diseases, such as atopic dermatitis and psoriasis, are known to affect quality of life by heightening psychological distress. Knowledge about factors contributing to psychological distress is essential for supporting physicians in diagnostic and multidisciplinary treatment options for patients psychologically at risk.To examine whether generic physical, psychological and social factors relevant to patients with chronic diseases might contribute to psychological distress in adults with psoriasis and atopic dermatitis.Self-report data on clinical skin status, physical symptoms of itching and fatigue, impact of the disease on daily life, illness cognitions and social support were collected from 128 patients with psoriasis and 120 patients with atopic dermatitis (aged over 16 years).For patients with either skin disease, clinical status and physical symptoms of itching scarcely affected psychological distress. Instead, higher levels of fatigue, perceived helplessness and less social support best predicted psychological distress in patients with both skin diseases in multiple regression analyses.Results demonstrate that generic physical, psychological and social aspects play a role in chronic skin diseases and suggest that multidisciplinary care for patients with psoriasis and atopic dermatitis can be greatly improved by integrating common screening and treatment components for chronic diseases.
Series Introduction: Heparan sulfate proteoglycans: intricate molecules with intriguing functions
Authors: Renato V. Iozzo
Journal: Journal of Clinical Investigation (2001)

The term heparan sulfate proteoglycan (HSPG) refers to a dichotomous structure, a protein coupled to a unique glycosaminoglycan chain characterized by a linear array of alternating disaccharide units. Both the protein core and the side chains undergo a series of modification reactions, which endow them with a very complex fabric (1). The final product is a sophisticated compound that can fluctuate in size, fine structure, and biology (2–5). The complexity of a usual heparan sulfate chain, for instance, can easily surpass that of common nucleic acids (6, 7).

The field of proteoglycan research is nearly equally split into two factions: those who feel that heparan sulfate is the prima donna, with the protein core being just a carrier, and those who feel that there would be no role for heparan sulfate without the protein core. The truth, as usual, is in the middle. Both possess unique features that in some respects act synergistically to provide the maximal strength of signaling and biological activity. This Perspective series, motivated by the recent flurry of discoveries, has been coordinated to provide a balanced view of the most recent advances in the field of HSPG research. The development of novel experimental strategies for decoding the sequence of heparan sulfate (8–10), together with the availability of antibodies specific for heparan sulfate epitopes (11), holds promise for deciphering the functional specificity of heparan sulfate in tissues. The medical importance is underscored by the direct involvement of HSPGs in various human diseases involving the musculoskeletal system, such as the Schwartz-Jampel chondrodystrophic myotonia (12) and the dyssegmental dysplasia Silverman-Handmaker type (13), overgrowth syndrome (Simpson-Golabi-Behmel) (14), or hereditary bone disorders (hereditary multiple exostoses) (15).
Research governance impediments to clinical trials: a retrospective survey
Authors: R. A.-S. Salman, T. M Brock, M. S Dennis, P. A G Sandercock, P. M White, C. Warlow
Journal: Journal of the Royal Society of Medicine (2007)

ObjectiveWe sought to evaluate the delays, between-centre variations in practice, and opportunity costs attributable to delays in research governance approval of clinical trials in the United Kingdom. SettingResearch and Development (R&D) departments at 50 UK National Health Service hospital trusts governing 57 hospital sites. ParticipantsR&D departments participating in four randomized multicentre clinical trials coordinated by our Neurosciences Trials Unit. ResultsOnly half of the R&D departments used the UK online R&D form. Only a single copy of the application was required by 96% of R&D departments. The median delay between application and research governance approval was 44 working days (interquartile range 23–80). A delay of >20 working days was incurred by 43 applications (75%), of which 24 (56%) were not explicable and 11 (20%) were attributable to local funding negotiations. Based on the trial randomization rates at each centre, 108 patients (17% of all patients randomized) could have been randomized during the delay, at a crude cost to funding agencies of £53,743; if a four week delay was deemed acceptable, 75 patients (12% of all patients randomized) could have been randomized during unacceptable delays, at a crude cost to funding agencies of £37,700. ConclusionsThe UK research governance system incurs unacceptably long and costly delays for clinical trials. Urgent reform is needed, including rapid design and uniform implementation of the 'bureaucracy busting' measures in Best Research for Best Health